Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
4SCAR-276
/
SZGIMI
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
|
|||||||||
4SCAR-276
/
SZGIMI
New P1/2 trial:
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
(clinicaltrials.gov) - Jun 16, 2020
P1/2
, N=100, Recruiting,
Sponsor: Shenzhen Geno-Immune Medical Institute